Molina Healthcare vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Long Beach CA Medicaid managed care (NYSE: MOH) ~$38.7B FY2024 revenue; 5.7M members in 19 states, Medicaid redetermination management, D-SNP growth competing with Centene and Elevance.
About
Molina Healthcare, Inc. is a Long Beach, California-based managed care organization — publicly traded on the New York Stock Exchange (NYSE: MOH) as an S&P 500 Health Care component — providing Medicaid, Medicare, and Marketplace (Affordable Care Act exchange) health insurance through state-contracted managed care plans to approximately 5.7 million low-income, elderly, and disabled members across 19 states, with revenues generated primarily from per-member-per-month (PMPM) capitation payments received from state Medicaid agencies and CMS Medicare programs. In fiscal year 2024, Molina Healthcare reported revenues of approximately $38.7 billion — primarily from Medicaid capitation payments from state Medicaid agencies that contract with Molina to administer benefits for enrolled beneficiaries — generating net income impacted by elevated medical costs in the Marketplace segment as post-COVID health utilization normalization drove medical loss ratios above expectations. CEO Joseph Zubretsky's strategy of disciplined Medicaid contract renewal and Medicaid redetermination management positioned Molina for the 2023-2024 Medicaid unwinding — the federal pandemic-era continuous enrollment requirement expiration required states to redetermine eligibility for all Medicaid enrollees, with Molina proactively assisting ineligible members transition to Marketplace plans to retain the relationship. Molina's marketplace business expansion (Affordable Care Act exchange plans in new states and existing markets) provides enrollment growth offsetting Medicaid membership losses from redetermination, while Medicare Dual Eligible Special Needs Plans (D-SNPs — serving members eligible for both Medicaid and Medicare) represent the highest-growth and highest-margin Molina product line.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.